scispace - formally typeset
V

Vani Vannappagari

Researcher at Research Triangle Park

Publications -  44
Citations -  1060

Vani Vannappagari is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Medicine & Regimen. The author has an hindex of 10, co-authored 35 publications receiving 807 citations. Previous affiliations of Vani Vannappagari include University of North Carolina at Chapel Hill & ViiV Healthcare.

Papers
More filters
Journal ArticleDOI

The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.

TL;DR: The magnitude and variation in global, regional, and country-level prevalence rates of G6PD deficiency are of public health import, particularly in planning programs to improve neonatal health and in the distribution of various medications, especially antimalarial drugs, as G6 PD deficiency is most prevalent in malaria-endemic areas.
Journal ArticleDOI

Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case–control study of African Americans and whites

TL;DR: The MnSOD genotype may contribute to an increased risk of breast cancer in the presence of specific environmental exposures and provide further evidence for the importance of reactive oxygen species and of oxidative DNA damage in the etiology of Breast cancer.
Journal ArticleDOI

Psychiatric Symptoms in Patients Receiving Dolutegravir.

TL;DR: Analysis of 3 different data sources shows that, similar to other frequently prescribed anchor drugs to treat HIV infection, PSs are also reported in DTG-treated patients.
Journal ArticleDOI

Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy

TL;DR: The prevalence of severe thrombocytopenia was low, it occurred at levels associated with bleeding and was persistent among a small proportion of patients despite receipt of HAART.
Journal ArticleDOI

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study

TL;DR: Frequency of HLA-B*57:01 screening increased steadily since its first inclusion in treatment guidelines in the United States, accompanied by a decreasing incidence of definite or probable hypersensitivity reactions over the same period.